210 related articles for article (PubMed ID: 24288037)
1. Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease.
Francis JS; Markov V; Leone P
J Inherit Metab Dis; 2014 May; 37(3):369-81. PubMed ID: 24288037
[TBL] [Abstract][Full Text] [Related]
2. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
3. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.
Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B
J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190
[TBL] [Abstract][Full Text] [Related]
4. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
5. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model.
Becker I; Wang-Eckhardt L; Eckhardt M
J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891
[TBL] [Abstract][Full Text] [Related]
6. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
7. Aspartoacylase supports oxidative energy metabolism during myelination.
Francis JS; Strande L; Markov V; Leone P
J Cereb Blood Flow Metab; 2012 Sep; 32(9):1725-36. PubMed ID: 22617649
[TBL] [Abstract][Full Text] [Related]
8. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
9. Redirecting
Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G
JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442
[TBL] [Abstract][Full Text] [Related]
10. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
Baslow MH; Guilfoyle DN
Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678
[TBL] [Abstract][Full Text] [Related]
11. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D
J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719
[TBL] [Abstract][Full Text] [Related]
12. Canavan disease: a white matter disorder.
Kumar S; Mattan NS; de Vellis J
Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
[TBL] [Abstract][Full Text] [Related]
13. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
[TBL] [Abstract][Full Text] [Related]
14. Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease.
Kirmani BF; Jacobowitz DM; Kallarakal AT; Namboodiri MA
Brain Res Mol Brain Res; 2002 Nov; 107(2):176-82. PubMed ID: 12487123
[TBL] [Abstract][Full Text] [Related]
15. Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination.
Mattan NS; Ghiani CA; Lloyd M; Matalon R; Bok D; Casaccia P; de Vellis J
Neurobiol Dis; 2010 Nov; 40(2):432-43. PubMed ID: 20637282
[TBL] [Abstract][Full Text] [Related]
16. Astroglial redistribution of aquaporin 4 during spongy degeneration in a Canavan disease mouse model.
Clarner T; Wieczorek N; Krauspe B; Jansen K; Beyer C; Kipp M
J Mol Neurosci; 2014 May; 53(1):22-30. PubMed ID: 24272958
[TBL] [Abstract][Full Text] [Related]
17. Dietary treatment proposed for Canavan's disease.
Chen V
Lancet Neurol; 2005 May; 4(5):273. PubMed ID: 15861552
[No Abstract] [Full Text] [Related]
18. Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease.
Arun P; Madhavarao CN; Moffett JR; Hamilton K; Grunberg NE; Ariyannur PS; Gahl WA; Anikster Y; Mog S; Hallows WC; Denu JM; Namboodiri AM
J Inherit Metab Dis; 2010 Jun; 33(3):195-210. PubMed ID: 20464498
[TBL] [Abstract][Full Text] [Related]
19. Defective myelin lipid synthesis as a pathogenic mechanism of Canavan disease.
Namboodiri AM; Moffett JR; Arun P; Mathew R; Namboodiri S; Potti A; Hershfield J; Kirmani B; Jacobowitz DM; Madhavarao CN
Adv Exp Med Biol; 2006; 576():145-63; discussion 361-3. PubMed ID: 16802710
[No Abstract] [Full Text] [Related]
20. Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease.
Kumar S; Biancotti JC; Matalon R; de Vellis J
J Neurosci Res; 2009 Nov; 87(15):3415-27. PubMed ID: 19739253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
